Rigel Pharmaceuticals, Inc. (RIGL)
| Market Cap | 837.18M +15.5% |
| Revenue (ttm) | 288.21M +2.2% |
| Net Income | 307.19M +171.1% |
| EPS | 15.38 +148.3% |
| Shares Out | 18.83M |
| PE Ratio | 2.89 |
| Forward PE | 13.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,587 |
| Open | 45.94 |
| Previous Close | 45.69 |
| Day's Range | 43.84 - 45.94 |
| 52-Week Range | 24.95 - 52.61 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 64.40 (+44.85%) |
| Earnings Date | Nov 5, 2026 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test;... [Read more]
Financial Performance
In 2025, Rigel Pharmaceuticals's revenue was $294.28 million, an increase of 64.15% compared to the previous year's $179.28 million. Earnings were $367.02 million, an increase of 1999.08%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price target is $64.4, which is an increase of 44.85% from the latest price.
News
Rigel to Present at the Jefferies Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today annou...
Rigel Pharmaceuticals price target raised to $86 from $83 at Citi
Citi raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $86 from $83 and keeps a Buy rating on the shares. The company posted a stronger than expected start…
Rigel Pharmaceuticals price target raised to $47 from $43 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $47 from $43 and keeps a Neutral rating on the shares.
Rigel Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 net product sales reached a record $72.3 million, with $13.2 million net income and $6.6 million from VEPPANU in its early U.S. launch. FY2026 revenue guidance was narrowed, while R289 enrollment and dose selection remain on track ahead of a 2027 registrational program.
Rigel Pharmaceuticals Quarterly report: Q3 2026
Rigel Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 5, 2026.
Rigel Pharmaceuticals Earnings release: Q3 2026
Rigel Pharmaceuticals released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Rigel Pharmaceuticals Slides: Q3 2026
Rigel Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Rigel Pharmaceuticals narrows 2026 revenue view to $290M-$295M from $285M-$295M
2026 revenue consensus $305.73M. Revenue guidance excludes Veppanu. Continues to anticipate it will report positive net income for the full year 2026, while funding existing and new clinical developme...
Rigel Pharmaceuticals reports Q3 EPS 65c, consensus 96c
Reports Q3 revenue $80.9M, consensus $80.1M. “Veppanu’s launch marks an exciting and transformational milestone for Rigel and we are very pleased with the initial uptake. In the first six weeks…
Rigel Reports Third Quarter 2026 Financial Results
Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 million VEPPANU™ (v...
Rigel reports data from Phase 1b clinical study of R2891
Rigel Pharmaceuticals (RIGL) announced that data from the ongoing Phase 1b clinical study of R2891, a potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4, or IRAK1/4, in…
Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or...
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close on...
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and patient-rep...
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. In...
Rigel Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A four-part growth strategy is driving expansion, highlighted by the VEPPANU acquisition and launch, which targets a billion-dollar breast cancer market. The pipeline, led by R289 in MDS, shows promising clinical results, while financials remain strong with raised revenue guidance.
Rigel Pharmaceuticals Slides: H.C. Wainwright 28th Annual Global Investment Conference
Rigel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Rigel Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Four strategic imperatives drive growth, highlighted by the rapid U.S. launch of VEPPANU, a first-in-class PROTAC for metastatic breast cancer with billion-dollar potential. R289 in lower-risk MDS shows promising efficacy, and strong financials support continued pipeline expansion.
Rigel Pharmaceuticals Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Rigel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today annou...
Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler
Piper Sandler raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $49 from $40 on a solid quarter, layering in Veppanu. The firm keeps a Neutral rating on the…
Rigel Pharmaceuticals’ Veppanu available for metastatic breast cancer
Rigel Pharmaceuticals (RIGL) announced Veppanu – vepdegestrant – is now available by prescription in the U.S. for the treatment of adults with estrogen receptor-positive/human epidermal growth factor ...
Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $85 from $57 and keeps a Buy rating on the shares after the company announced…
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif.,...
Rigel Pharmaceuticals price target raised to $83 from $81 at Citi
Citi raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $83 from $81 and keeps a Buy rating on the shares. The firm says the company’s Q2 report support…